Stephanie L. Graff, MD, FACP

Stephanie L. Graff, MD, FACP, FASCO, discusses current strategies for fertility preservation in patients with breast cancer.

Stephanie L. Graff, MD, FACP, FASCO, discusses data supporting the use of GnRH agonists for premenopausal women with breast cancer undergoing chemotherapy.

Bora Lim, MD, of The University of Texas MD Anderson Cancer, and Stephanie Graff, MD, of Brown University Health, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in breast cancer presented during the 2024 San Antonio Breast Cancer Symposium.

Drs Park and Graff discuss the evolution of treatment for patients with metastatic HR-positive breast cancer, including the role of CDK4/6 inhibitors.

Drs Graff, Mahtani, McCann, and Rugo share moments that sparked their interest in oncology and setbacks they overcame when building their careers.

Stephanie L. Graff, MD, discusses the trajectory of her career growth in breast oncology and explains how different factors can play a role in an oncologist’s career path.

Stephanie L. Graff, MD, discusses findings from a pilot study exploring the association between disease recurrence and circulating tumor DNA positivity in patients with hormone receptor–positive, HER2-negative, node-positive, high-risk, early breast cancer who have received adjuvant treatment of abemaciclib and endocrine therapy.

Stephanie L. Graff, MD, discusses the advantages of interrupting endocrine therapy in premenopausal patients with endocrine-responsive breast cancer who are seeking to conceive, based on findings from the phase 3 POSITIVE trial.

Expert medical oncologists take a step into the future and discuss developments within the adjuvant setting of early-stage breast cancer they are most excited about.

Stephanie Graff, MD, and Rachel Layman, MD, review common toxicities and adverse effects to watch out for with endocrine therapy and CDK4/6 inhibitors, and how to manage these.

Expert medical oncologists talk about the impact of NATALEE trial data on their medical practice.

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the NATALEE trial, which evaluated adjuvant ribociclib + endocrine therapy versus endocrine therapy alone in patients with HR+/HER2− early breast cancer.

Stephanie Graff, MD, describes her impression of the case and discusses the risk for recurrence in this particular patient.

Rachel Layman, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Experts in breast oncology discuss how they select endocrine therapy in BRCA1/BRCA2+ breast cancer.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how they would apply the results of the monarchE trial to clinical case scenarios.

Rachel Layman, MD, summarizes how to dose CDK4/6 inhibitors in different clinical settings.

Experts in breast oncology review age-dependent outcomes with CDK 4/6 inhibitors.

Stephanie Graff, MD, and Rachel Layman, MD, discuss how to individualize care with CDK4/6 inhibitors in patients with high-risk early breast cancer.

Stephanie Graff, MD, and Rachel Layman, MD, discuss the design and results of the monarchE trial, which evaluated abemaciclib plus endocrine therapy for HR+, HER2 negative, node positive, high-risk early breast cancer.

Expert medical oncologists provide an overview of current endocrine therapy approved for early-stage breast cancer.

Rachel Layman, MD, describes her impression of the case and discusses risk assessment and a treatment plan for the patient.

Stephanie Graff, MD, presents a clinical case of a patient who is diagnosed with HR+ early-stage breast cancer.

Stephanie L. Graff, MD, discusses current and planned investigations of the emerging antibody-drug conjugate datopotamab deruxtecan in patients with metastatic hormone receptor–positive breast cancer and triple-negative breast cancer.

Stephanie L. Graff, MD, discusses the evaluation of trastuzumab deruxtecan in patients with HER2-zero metastatic breast cancer in the ongoing, phase 2 DESTINY-Breast06 trial.

Stephanie L. Graff, MD, discusses data from an exploratory analysis of patients with HER2-positive breast cancer and brain metastases enrolled to the phase 2 HER2CLIMB study, and emphasizes the need for such research efforts to move the needle forward for this population.

Before closing out their panel on HER2+ breast cancer, expert oncologists share closing thoughts and their excitement for the evolving treatment landscape.

Panelists focus on clinical trial data driving use of novel agents in the setting of HER2-low breast cancer and consider how they might select specific therapies.

Stephanie L. Graff, MD, discusses the initial steps for treating patients with metastatic hormone receptor–positive breast cancer.

Comprehensive insight on the novel treatment strategies available for patients diagnosed with HER2-low breast cancer.